Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 14/20 | 0.60 |
| ▸ | CA2 | P00918 | 6/20 | 0.60 |
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 14/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29151571 | 0.78 | ELANE (0.78) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL18411793 | 0.77 | CA9 (0.37) | CA9CA2ELANECA12LMNA | |
| SCHEMBL11773913 | 0.76 | ELANE (0.58) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL29386930 | 0.75 | CA9 (0.60) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL358766 | 0.75 | CA9 (0.60) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL358829 | 0.75 | CA9 (0.60) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL29165711 | 0.75 | CA9 (0.60) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL1779607 | 0.75 | ELANE (0.61) | CA9CA2ELANECA12CYP2D6 | |
| Saccharin Calcium SCHEMBL29394622 | 0.75 | CA9 (0.60) | CA9CA2ELANECA12CYP2D6 | |
| SCHEMBL29853810 | 0.75 | CA9 (0.60) | CA9CA2ELANECA12CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402652-B2 | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C G | 2008-07-22 | — | — | US | claimed |
| US-20060142182-A1 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-06-29 | — | — | US | claimed |
| US-20060058221-A1 | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | claimed |
| US-20060058219-A1 | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | claimed |
| EP-4724590-A1 | ADENO-ASSOCIATED VIRUS FORMULATIONS | 4D Molecular Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12553062-B2 | AAV compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20250255862-A1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | AMGEN INC. | 2025-08-14 | — | — | US | disclosed |
| US-12295952-B2 | Methods of treating heart failure with cardiac sarcomere activators | CYTOKINETICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| US-12257277-B2 | Adeno-associated virus formulations | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-03-25 | — | — | US | disclosed |
| EP-4512470-A2 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | Amgen Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250002868-A1 | ADENO-ASSOCIATED VIRUS SEPARATION ON A CATION EXCHANGER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20060058221-A1 | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | disclosed |
| US-20060058221-A1 | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | disclosed |
| US-20060058219-A1 | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | disclosed |
| US-20060058219-A1 | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | disclosed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-4867977-A | OF GLUCONIC OR LACTIC ACID, CALCIUM CARBONATE, ORGANIC POLYCARBOXYLIC ACID, TREATMENT OF CALCIUM DEFICIENCY | SANDOZ, LTD. (CH) | 1989-09-19 | — | — | US | disclosed |
| US-4135028-A | PROCESS FOR FIREPROOFING SYNTHETIC FIBER MATERIALS WITH SULPHONAMIDES | CIBA-GEIGY CORPORATION (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142182-A1 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | PRLHR, GIPR, NTSR1 | CA9 2430/4885CA2 2824/4885ELANE 1336/4885 |
| US-20250255862-A1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | TNNC1, TNNT2, TNNI3 | CA9 4613/4885CA2 1212/4885ELANE 1994/4885 |
| US-12295952-B2 | Methods of treating heart failure with cardiac sarcomere activators | TNNC1, TNNT2, TNNI3 | CA9 4613/4885CA2 1212/4885ELANE 1994/4885 |
| US-12553062-B2 | AAV compositions | PRDM9, H1-10, SLC20A1 | CA9 182/4885CA2 2353/4885ELANE 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.